Vyne Therapeutics Correlations
| VYNE Stock | USD 2.70 0.05 1.82% |
The current 90-days correlation between Vyne Therapeutics and Akari Therapeutics PLC is 0.16 (i.e., Average diversification). The correlation of Vyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Vyne Therapeutics Correlation With Market
Modest diversification
The correlation between Vyne Therapeutics and DJI is 0.28 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Vyne Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Vyne |
Moving against Vyne Stock
| 0.53 | BCH | Banco De Chile Earnings Call Tomorrow | PairCorr |
| 0.32 | WF | Woori Financial Group Earnings Call This Week | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Vyne Stock performing well and Vyne Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vyne Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AKTX | 5.77 | (0.56) | 0.00 | 1.41 | 0.00 | 11.21 | 47.27 | |||
| SLRX | 7.57 | 1.44 | 0.23 | 0.50 | 6.22 | 11.41 | 161.82 | |||
| AXLA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| MGTA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| HSTO | 4.99 | (0.99) | 0.00 | 1.12 | 0.00 | 10.80 | 93.31 | |||
| FWBI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SABS | 6.68 | 0.43 | 0.03 | (0.76) | 11.08 | 16.77 | 101.06 | |||
| VCNX | 7.51 | (1.05) | 0.00 | 1.18 | 0.00 | 12.36 | 75.17 | |||
| GOVX | 5.20 | 0.37 | 0.04 | (0.41) | 5.32 | 9.26 | 77.95 | |||
| CBIO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Vyne Therapeutics Corporate Management
| Russell DPhil | VP Devel | Profile | |
| Iain Stuart | Chief Officer | Profile | |
| MS MD | Consultant | Profile | |
| Subhashis MD | Senior Development | Profile | |
| David Schuz | VP Property | Profile | |
| Faad MD | Consultant | Profile |